HCA
CLDX icon

Harbour Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

Harbour Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-883
Closed -$208K – 223
2015
Q4 		$208K Buy
+883
New +$192K 0.11% 208
2015
Q3 		– Sell
-667
Closed -$252K – 197
2015
Q2 		$252K Buy
+667
New +$265K 0.16% 169

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Harbour Capital Advisors's CLDX Position: Q1 2016 in Review

Harbour Capital Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 883 shares — an estimated $208K sold.

Harbour Capital Advisors first reported a position in CLDX in Q2 2015 and held it in 2 quarters. The position peaked at $252K in Q2 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Harbour Capital Advisors reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Harbour Capital Advisors sold 883 Celldex Therapeutics shares in Q1 2016, an estimated $208K.
  • Harbour Capital Advisors first reported a position in Celldex Therapeutics in Q2 2015 and held it in 2 quarters.
  • Harbour Capital Advisors's Celldex Therapeutics position peaked at $252K in Q2 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Harbour Capital Advisors's 13F filing for Q1 2016, filed 13 Sep 2016.